Cardiovascular Research
Page 1 • 2 itemsUnlock global pharma market insights into cardiovascular research. Stay ahead with critical data for investors, BD, and analysts.
Lilly's Foundayo Shows 57% Mortality Reduction in Landmark ACHIEVE-4 Diabetes Trial
Eli Lilly's Foundayo (orforglipron) demonstrates superior cardiovascular outcomes with 57% lower all-cause death risk vs insulin glargine in Phase 3 trial.
Vasa Therapeutics Partners with Eli Lilly's TuneLab AI Platform for CAMKII Inhibitor Development
Vasa Therapeutics announces partnership with Eli Lilly's TuneLab AI platform to accelerate CAMKII delta inhibitor development for cardiovascular disorders.